Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Heart FailureDiabetes
Interventions
DRUG

Dapagliflozin

Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor

DRUG

Placebo

Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator

Trial Locations (1)

DD1 9SY

Ninewells Hospital and Medical School, Dundee

All Listed Sponsors
collaborator

European Foundation for the Study of Diabetes

OTHER

lead

University of Dundee

OTHER

NCT02397421 - Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes | Biotech Hunter | Biotech Hunter